Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)
Bissonnette, R., Luger, T., Thaçi, D., Toth, D., Lacombe, A., Xia, S., Mazur, R., Patekar, M., Charef, P., Milutinovic, M., Leonardi, C., Mrowietz, U.
Published in Journal of the European Academy of Dermatology and Venereology (01.09.2018)
Published in Journal of the European Academy of Dermatology and Venereology (01.09.2018)
Get full text
Journal Article
Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled trial
Bodemer, C., Kaszuba, A., Kingo, K., Tsianakas, A., Morita, A., Rivas, E., Papanastasiou, P., Keefe, D., Patekar, M., Charef, P., Zhang, L., Cafoncelli, S., Papavassilis, C.
Published in Journal of the European Academy of Dermatology and Venereology (01.04.2021)
Published in Journal of the European Academy of Dermatology and Venereology (01.04.2021)
Get full text
Journal Article
Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a double‐blind phase 3b trial (CLARITY)
Bagel, J., Blauvelt, A., Nia, J., Hashim, P., Patekar, M., Vera, A., Ahmad, K., Paguet, B., Xia, S., Muscianisi, E., Lebwohl, M.
Published in Journal of the European Academy of Dermatology and Venereology (01.01.2021)
Published in Journal of the European Academy of Dermatology and Venereology (01.01.2021)
Get full text
Journal Article
THU0411 Secukinumab Efficacy in Anti-TNF-Naive and Anti-TNF-IR Patients with Psoriatic Arthritis: Results of a Phase 3 Multicenter, Double-Blind, Placebo-Controlled Study (Future 2)
Kavanaugh, A., McInnes, I.B., Hall, S., Chinoy, H., Kivitz, A., Kandala, S., Patekar, M., Mpofu, S.
Published in Annals of the rheumatic diseases (01.06.2015)
Published in Annals of the rheumatic diseases (01.06.2015)
Get full text
Journal Article
THU0418 Secukinumab Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from the Phase 3 Future 2 Study
Gottlieb, A., McInnes, I.B., Mease, P., Rahman, P., Kandala, S., Patekar, M., Mpofu, S.
Published in Annals of the rheumatic diseases (01.06.2015)
Published in Annals of the rheumatic diseases (01.06.2015)
Get full text
Journal Article
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
McInnes, Iain B, Prof, Mease, Philip J, Prof, Kirkham, Bruce, MD, Kavanaugh, Arthur, Prof, Ritchlin, Christopher T, Prof, Rahman, Proton, Prof, van der Heijde, Désirée, Prof, Landewé, Robert, Prof, Conaghan, Philip G, Prof, Gottlieb, Alice B, Prof, Richards, Hanno, MD, Pricop, Luminita, MD, Ligozio, Gregory, MSc, Patekar, Manmath, MD, Mpofu, Shephard, MD
Published in The Lancet (British edition) (19.09.2015)
Published in The Lancet (British edition) (19.09.2015)
Get full text
Journal Article